Kymera director granted options on 6,068 shares

Kymera Therapeutics director Jeffrey W. Albers received a new stock option grant covering 6,068 shares of common stock.

Rhea-AI Filing Summary

Kymera Therapeutics director Jeffrey W. Albers received a new stock option grant covering 6,068 shares of common stock. The options have an exercise price of $99.87 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the next annual stockholder meeting. This is a compensation-related award rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 6,068 shares

Grant/Award 1 txn

Insider Albers Jeffrey W.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,068	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 6,068 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Key Figures

Option grant size: 6,068 shares Exercise price: $99.87 per share Expiration date: June 23, 2036 +1 more

4 metrics

Option grant size 6,068 shares Stock option covering common stock

Exercise price $99.87 per share Stock option strike price

Expiration date June 23, 2036 Option term end

Vesting trigger date June 24, 2027 Earlier of this date or next annual meeting

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, vest in full, annual meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest in full financial

"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027..."

annual meeting of the Issuer's stockholders financial

"...and (ii) the date of the next annual meeting of the Issuer's stockholders."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kymera Therapeutics (KYMR) report for Jeffrey W. Albers?

Kymera Therapeutics reported that director Jeffrey W. Albers received a stock option grant for 6,068 shares. The award is compensation-related, not an open-market trade, giving him the right to buy common stock at a fixed price if the options vest and are exercised.

What is the exercise price of the new Kymera Therapeutics (KYMR) stock options?

The new stock options granted to Jeffrey W. Albers have an exercise price of $99.87 per share. This means he can buy up to 6,068 Kymera Therapeutics common shares at $99.87 if the options vest and he chooses to exercise them before expiration.

When do Jeffrey W. Albers’ Kymera Therapeutics (KYMR) options vest?

The options granted to Jeffrey W. Albers vest in full on the earlier of June 24, 2027 or the date of Kymera Therapeutics’ next annual stockholders meeting. Full vesting means all 6,068 underlying shares become exercisable at once when that trigger date occurs.

When do the newly granted Kymera Therapeutics (KYMR) stock options expire?

The stock options granted to Jeffrey W. Albers expire on June 23, 2036. After that date, any unexercised portion of the 6,068-share option award will lapse, and he will no longer have the right to purchase Kymera Therapeutics common stock at the $99.87 exercise price.

Is the Kymera Therapeutics (KYMR) Form 4 transaction a stock buy or sell?

The Form 4 reports an acquisition of derivative securities through a stock option grant, not a buy or sell of common shares in the market. It reflects a compensation award giving Jeffrey W. Albers the right to buy shares in the future at a fixed price if exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 06:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Albers Jeffrey W.

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$99.87	06/24/2026		A		6,068		(1)	06/23/2036	Common Stock	6,068	$0	6,068	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)